Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT04543279 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Myelofibrosis
Thrombocytopenia

Interventions

DRUG: Fostamatinib
DRUG: Ruxolitinib

Sponsor

Washington University School of Medicine

Collaborators

[object Object]